Enliven Therapeutics (NASDAQ:ELVN) COO Anish Patel Sells 6,663 Shares of Stock

by · The Cerbat Gem

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 6,663 shares of Enliven Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $21.02, for a total value of $140,056.26. Following the sale, the chief operating officer directly owned 263,311 shares of the company’s stock, valued at $5,534,797.22. This trade represents a 2.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anish Patel also recently made the following trade(s):

  • On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.40, for a total transaction of $116,005.80.
  • On Tuesday, October 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.10, for a total value of $134,006.70.

Enliven Therapeutics Stock Up 3.5%

NASDAQ:ELVN traded up $0.68 during mid-day trading on Wednesday, reaching $20.17. 1,095,001 shares of the stock were exchanged, compared to its average volume of 432,699. The stock has a market capitalization of $1.20 billion, a P/E ratio of -10.96 and a beta of 0.35. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $25.37. The company has a 50 day simple moving average of $20.86 and a 200-day simple moving average of $20.43.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. As a group, research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ELVN shares. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.20.

Check Out Our Latest Research Report on Enliven Therapeutics

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently bought and sold shares of ELVN. Quantbot Technologies LP acquired a new stake in Enliven Therapeutics in the first quarter valued at $60,000. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after buying an additional 930 shares in the last quarter. AlphaQuest LLC acquired a new stake in Enliven Therapeutics in the 3rd quarter valued at about $96,000. Tower Research Capital LLC TRC increased its holdings in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after acquiring an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS raised its position in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after acquiring an additional 2,500 shares during the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

See Also